Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
19–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants administered with MabThera subcutaneously within the approved indication in Korea
Participants previously untreated with MabThera subcutaneously
Relapsed or chemoresistant follicular lymphoma (FL) (B, C, and D type by international working formulation classification of B-cell NHL) participants
Previously untreated FL participants in combination with chemotherapy
Participants who are treated with maintenance therapy after the treatment of FL participants responding to induction therapy.
Cluster of differentiation 20-positive, diffuse large B-cell NHL participants in combination with cyclophosphamide, doxorubicin, vincristine, and prednisolone (8 cycles) chemotherapy
\- Previously untreated or relapsed/refractory CLL participants in combination with chemotherapy
You may not be if
Pregnant or breastfeeding women
Participants who are out of locally approved indications, dosage, and administration including medication error
Contraindication in use by locally approved indications, dosage, and administration
Clareo Health | An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL)
